Gautam Patel is Director at Amneal Pharmaceuticals, Inc. (AMRX). They have made 6 open-market trades across 1 company since 2020, most recently 2026-08-10.
CIK 0001738054
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $1.4M since 2020, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AMRX | SELL · 10b5-1 | 2025-06-16 | 2025-06-18 | $8.02 | $1.5M | +2.2% | -0.7% | +21.3% |
| AMRX | SELL | 2025-06-10 | 2025-06-12 | $8.02 | $905K | +2.5% | +7.2% | +25.0% |
| AMRX | SELL · 10b5-1 | 2025-05-02 | 2025-05-06 | $8.00 | $69K | +5.1% | -0.8% | +10.1% |
| AMRX | SELL | 2025-04-01 | 2025-04-02 | $8.30 | $664K | -10.5% | -1.1% | +1.9% |
| AMRX | SELL | 2025-03-03 | 2025-03-05 | $8.90 | $712K | -1.5% | -15.7% | -14.9% |
| AMRX | SELL | 2025-02-03 | 2025-02-05 | $8.14 | $651K | -2.4% | +11.5% | -10.0% |
| AMRX | SELL · 10b5-1 | 2025-01-08 | 2025-01-10 | $8.01 | $1.0M | +11.9% | +1.0% | -11.4% |
| AMRX | SELL · 10b5-1 | 2025-01-02 | 2025-01-06 | $8.01 | $279K | +6.2% | +2.6% | -7.3% |
| AMRX | BUY | 2021-12-17 | 2021-12-20 | $4.21 | $211K | +2.6% | -4.5% | -13.3% |
| AMRX | BUY | 2020-03-02 | 2020-03-10 | $3.93 | $1.2M | +10.2% | +2.5% | +56.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.